Glimblist-M 2 Plus Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The combination of these two agents provides complementary mechanisms of action, resulting in effective blood glucose regulation in patients inadequately controlled by diet and exercise alone or by monotherapy. Glimblist-M 2 Plus Tablet PR is particularly beneficial for patients requiring dual therapy to achieve glycemic targets. It should be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea and diarrhea. Regular monitoring of blood glucose levels, renal function, and periodic assessment for potential adverse effects, including hypoglycemia and lactic acidosis, is recommended during therapy. This medication is contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to its components. Glimblist-M 2 Plus Tablet PR should be used under strict medical supervision as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modifications.